Cabotegravir/rilpivirine: Difference between revisions
From IDWiki
(Created page with "* Long-acting injectable medication used to treat HIV * Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary * Dosing ** 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks ** 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks ** Can be given ±1 week of target date ** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything) * Injectio...") |
No edit summary |
||
| Line 2: | Line 2: | ||
* Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary |
* Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary |
||
* Dosing |
* Dosing |
||
| − | ** 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks |
+ | ** '''Monthly:''' 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks |
| − | ** 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks |
+ | ** '''Every 2 monthly:''' 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks |
** Can be given ±1 week of target date |
** Can be given ±1 week of target date |
||
** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything) |
** If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything) |
||
| Line 9: | Line 9: | ||
* Injections |
* Injections |
||
** May need long needle to reach muscle in obese patients |
** May need long needle to reach muscle in obese patients |
||
| − | ** Often given as <u>r</u>ilpivirine into <u>r</u>ight buttock and cabotegravir into left |
+ | ** Often given as [[Rilpivirine|<u>r</u>ilpivirine]] into <u>r</u>ight buttock and cabotegravir into left |
* Virologic failures |
* Virologic failures |
||
** Occur despite perfect adherence |
** Occur despite perfect adherence |
||
| − | ** Increased if rilpivirine RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI |
+ | ** Increased if [[rilpivirine]] RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI |
* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection |
* Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection |
||
** Use with caution if risk factors for virologic failure; may warrant closer monitoring |
** Use with caution if risk factors for virologic failure; may warrant closer monitoring |
||
Revision as of 14:48, 2 July 2024
- Long-acting injectable medication used to treat HIV
- Studied after viral suppression with oral CAB/RPV, but this is not likely to be necessary
- Dosing
- Monthly: 600 mg/900 mg IM on week 1 followed by 400 mg/600 mg every 4 weeks
- Every 2 monthly: 600 mg/900 mg IM every 4 weeks for 2 doses followed by every 8 weeks
- Can be given ±1 week of target date
- If they are going to miss a dose, they should get bridge oral dosing (preference for oral CAB/RPV, but can be anything)
- Injections
- May need long needle to reach muscle in obese patients
- Often given as rilpivirine into right buttock and cabotegravir into left
- Virologic failures
- Occur despite perfect adherence
- Increased if rilpivirine RAMs, low 8-week trough levels, HIV-1 subtype A6 and A3, and with elevated BMI
- Contraindications: anticoagulation (given risk of IM bleeding), buttock implants, drug-drug interactions, and hepatitis B coinfection
- Use with caution if risk factors for virologic failure; may warrant closer monitoring
